Compare OPXS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | ANIX |
|---|---|---|
| Founded | 1987 | 1982 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 88.8M |
| IPO Year | 2009 | 2013 |
| Metric | OPXS | ANIX |
|---|---|---|
| Price | $13.97 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.10 | $8.67 |
| AVG Volume (30 Days) | 45.4K | ★ 223.3K |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | 12.82 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $24,530,000.00 | $210,000.00 |
| Revenue This Year | $39.17 | N/A |
| Revenue Next Year | $0.53 | N/A |
| P/E Ratio | $61.00 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.74 | $2.32 |
| 52 Week High | $17.76 | $5.46 |
| Indicator | OPXS | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 64.53 |
| Support Level | $12.46 | $2.90 |
| Resistance Level | $13.68 | $3.58 |
| Average True Range (ATR) | 0.78 | 0.25 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 78.05 | 87.80 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.